Juan Francisco Cabello, MD, on the History and Current State of Newborn Screening

Commentary
Video

The head of the Pediatric Neurology Fellowship Program at the University of Valparaíso in Chile discussed positive impact of newborn screening so far and work that still needs to be done.

“Newborn screening started in the 60s in the United States [and was intended as an equity tool] because the idea was to offer to all the American citizens at the time a dual screening to test for congenital hypothyroidism for phenylketonuria. But over time, other developed countries—those in Europe; Japan; Australia—started with their own newborn screening programs. But there are many areas in the world still that have no newborn screening for any condition. So today, 60 years after, newborn screening is one of the worst examples of inequities in global health...”

Newborn screening enables doctors to detect and begin treatment of genetic and other inborn diseases in children before symptoms even appear. In some diseases, this gives a critically important advantage in preventing or mitigating symptoms before irreversible damage occurs. As gene therapy rapidly comes of age, with more treatments for genetic disorders being evaluated and approved every year, newborn screening is arguably more important than ever. Despite this, many countries around the world have not yet implemented newborn screening as a standard practice for any of the diseases for which screening is possible.

Juan Francisco Cabello, MD, the head of the Pediatric Neurology Fellowship Program at the University of Valparaíso in Chile, is giving a presentation on the importance of newborn screening at the 148th Annual Meeting of the American Neurological Association, held September 9-12, 2023, in Philadelphia, Pennsylvania. The talk, entitled, “Ethical considerations of newborn metabolic screening in international settings” will focus on the disparity of newborn screening practices around the world and how addressing this issue can improve global health outcomes.

In an interview with CGTLive™ at the conference, Cabello discussed the key points of his presentation and gave some background on the history of newborn screening and the current state of this practice in different regions of the world today. He noted that newborn screening started in the US as far back as the 1960s and emphasized the importance of newborn screening as a tool for health equity.

REFERENCE
Cabello JF. Ethical considerations of newborn metabolic screening in international settings. Presented at the 148th Annual Meeting of the American Neurological Association, held September 9-12, 2023, in Philadelphia, Pennsylvania.
Recent Videos
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Lucas Harrington, PhD, the cofounder and chief scientific officer of Mammoth Biosciences
Stephanie Tagliatela on Researching AAV for Lennox-Gastaut, Alzheimer Disease, SCN9a Pain
Miloš Miljković, MD, on mRNA-CAR-T Descartes-08's Potential for Treating Myasthenia Gravis
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Related Content
© 2024 MJH Life Sciences

All rights reserved.